

# well

HAN-GINS Indxx Healthcare Innovation UCITS ETF - Acc

Factsheet | Data as of 28 Feb 2021

## Investment Objective

HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) is a UCITS compliant Exchange Traded Fund domiciled in Ireland. WELL tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return), an index designed to measure the performance of performance of large, mid and small-capitalisation companies primarily listed on an exchange in Developed and Emerging Markets that are involved in the Advanced Life Sciences & Smart Healthcare sector.

## Why WELL?



### High-conviction Megatrends

Participate in two of the most influential structural shifts taking place in our society - Digitalisation and Aging Populations



### Distinctive

Going far beyond traditional Big Pharma, WELL captures securities at the cross-roads of Medicine and Technology which are shaping the future of Healthcare



### Modern Portfolio Composition

The strategy is sub-divided into eight distinctive themes identified through a rigorous research process, which include companies at the forefront of Healthcare innovation



### True Representation

As innovation is not determined by geographical boundaries or the size of a company, the fund includes companies from both developed and emerging markets across all market cap ranges

## Key Risks

1. The value of equities and equity-related securities can be affected by daily stock and currency market movements.
2. Emerging & frontier markets are subject to greater market volatility than developed markets.
3. Investors' capital is fully at risk and investors may not get back the amount originally invested.
4. Exchange rate fluctuations could have a negative or positive effect on returns.

## Performance vs Index

Fund	1M	3M	6M	YTD	12M
WELL	-0.64%	6.45%	10.08%	0.39%	35.48%
IELXRNT	-0.61%	6.50%	10.30%	0.40%	36.31%

Source: Bloomberg, as of 28 Feb 2021. Performance for the fund and the index is shown in USD. Fund performance is shown net of fees with income reinvested where applicable. Please be aware that fees have a detrimental impact on the performance of an ETP. Past performance is not an indicator for future results.

## Trading Information

Exchange	Ticker	RIC	SEDOL	ISIN	CCY
LSE	WELL LN	HAWELL.L	BJVBGL7	IE00BJQTJ848	USD
LSE	WELP LN	WELP.L	BJVBGM8	IE00BJQTJ848	GBP
Borsa Italiana	WELL IM	WELL.MI	BHRWXD1	IE00BJQTJ848	EUR
Xetra	W311.GY	W311.DE	BJO2354	IE00BJQTJ848	EUR
SIX	WELL SW	WELL.S	BMYC3R3	IE00BJQTJ848	CHF

## Key Facts

Inception Date	04/04/2019
Index	Indxx Advanced Life Sciences & Smart Healthcare Healthcare Thematic Index
Asset Class	Equities
Number of Holdings	108
Base Currency	USD
Index PE Ratio	41.65
Index Dividend Yield (Est)	0.32%
Income Treatment	Accumulating
TER	59 bps
Rebalance Frequency	Annually, June
Fund Domicile	Ireland
Replication Style	Physical
Registered for Sale	UK, IE, IT, DE, AT, DK, FI, LU, NL, NO, SE, CH
UK Fund Reporting Status	Yes
UCITS Eligible	Yes
ISA Eligible	Yes
SIPP Eligible	Yes
Custodian	BNY Mellon
Portfolio Manager	Vident Investment Advisory, LLC
Net Assets of Fund	17,727,772.46 (USD)
Net Assets of Share Class	17,727,772.46 (USD)
Shares Outstanding	1,600,000

# well

HAN-GINS Indxx Healthcare Innovation UCITS ETF - Acc

Factsheet | Data as of 28 Feb 2021

## Index Information

Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return ) is managed according to a published, rules-based methodology. It is designed to measure the performance of an investable universe of publicly-traded companies that are involved in healthcare innovation. To be included, companies must derive revenue from themes including Robotics, Nanotechnology, Genome Sequencing, Healthcare Trackers, Biological Engineering , Bioinformatics, Neuroscience, Medical Devices For further information, visit [www.Indxx.com](http://www.Indxx.com)

## Index Performance and Volatility Indicators (USD)

Period	Return	Volatility
2016	0.06%	17.85%
2017	34.20%	10.12%
2018	6.56%	19.53%
2019*	25.40%	15.36%
2020	27.85%	29.55%
2021	0.39%	15.80%


\*Index data up to the 03/04/2019. Fund data from 04/04/2019

Performance before inception is based on back tested data. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of that strategy would have been. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. Past performance for the index is in USD and shown net of fees. Past performance and back tested index performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. It is provided for illustrative purposes only. Indices cannot be invested in directly. Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product. Source HANetf /Indxx.

## Top 10 Index Holdings (%)

Company	(%)	Company	(%)
Medtronic PLC	4.79%	Boston Scientific Corp	4.09%
Intuitive Surgical Inc	4.79%	Biogen Inc	3.89%
Illumina Inc	4.58%	Agilent Technologies Inc	3.79%
Edwards Lifesciences Corp	4.50%	DexCom Inc	3.68%
Align Technology Inc	4.14%	Zimmer Biomet Holdings Inc	3.40%

## Regional Exposure



United States	81.62%
Other	4.93%
Japan	4.84%
Switzerland	3.35%
China	2.89%
United Kingdom	2.36%

## Sub-Theme Breakdown

Sector	Weight (%)
Medical Devices	58.51%
Biological Engineering	21.59%
Genome Sequencing	7.51%
Neuroscience	6.55%
Robotics	4.85%
Bioinformatics	0.54%
Healthcare Tracker	0.45%

## ETF Partner

HAN-GINS Indxx Healthcare Innovation UCITS ETF has been developed by HANetf and Gins Global Investment Management, a multi-billion dollar asset management company founded in 2000 with operations in North America, Africa, Middle East and Asia-Pacific. [www.ginsglobal.com](http://www.ginsglobal.com)



## About HANetf

HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern and innovative exposures to European ETF investors. Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs.

**well**

HAN-GINS Indxx Healthcare Innovation UCITS ETF - Acc

Factsheet | Data as of 28 Feb 2021

IMPORTANT INFORMATION This factsheet is approved for professional use only.

**COMMUNICATIONS ISSUED IN THE EUROPEAN ECONOMIC AREA ("EEA")**

The content in this document is issued by HANetf Management Limited ("HML") acting in its capacity as management company of HANetf ICAV. HML is authorised and regulated by the Central Bank of Ireland. HML is registered in Ireland with registration number 621172.

**COMMUNICATIONS ISSUED IN THE UK**

The content in this document is issued by HANetf Limited ("HANetf"), an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority (FCA FRN 606792). HANetf is registered in England and Wales with registration number 10697042.

This communication has been prepared for professional investors, but the Exchange Traded Funds ("ETFs") set out in this communication may be available in some jurisdictions to any investors. Please check with your broker or intermediary that the relevant ETF is available in your jurisdiction and suitable for your investment profile.

Past performance is not a reliable indicator of future performance. The price of the ETFs may vary and they do not offer a fixed income.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements.

The content of this document does not constitute an investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment. An investment in an exchange traded product is dependent on the performance of the underlying asset class, less costs, but it is not expected to track that performance exactly. The ETFs involve numerous risks including among others, general market risks relating to underlying adverse price movements in an Index or underlying asset class and currency, liquidity, operational, legal and regulatory risks.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of securities in the United States or any province or territory thereof, where HANetf ICAV or their ETFs are authorised or registered for distribution and where no prospectus of HANetf ICAV has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. HANetf ICAV, nor any securities issued by it, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

HANetf ICAV is an open-ended Irish collective asset management vehicle issuing under the terms in the Prospectus and relevant Supplement approved by the Central Bank of Ireland ("CBI") ("Prospectus") is the issuer of the ETFs. Investors should read the current version of the Prospectus before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the ETFs. Any decision to invest should be based on the information contained in the Prospectus.

The Prospectus can all be downloaded from [www.hanetf.com](http://www.hanetf.com).